Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells

Nitric Oxide - Biology and Chemistry

Volumn 19, Issue 2, 2008, Pages 177-183

  Mijatovic, Sanja ^a   Maksimovic Ivanic, Danijela ^a   Mojic, Marija ^a   Malaponte, Graziella ^b   Libra, Massimo ^b   Cardile, Vera ^b   Miljkovic, Djordje ^a   Harhaji, Ljubica ^a   Dabideen, Darrin ^c   Cheng, Kai Fan ^c   Bevelacqua, Ylenia ^b   Donia, Marco ^b   Garotta, Gianni ^d   Al Abed, Yousef ^b   Stosic Grujicic, Stanislava ^a   Nicoletti, Ferdinando ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF CATANIA   (Italy)

^c North Shore Long Island Jewish Health System ^*  (United States)

^d Ganial Immunotherapeutics Inc   (United States)

Author keywords

A375 melanoma cells; Apoptosis; GIT 27NO; Nitric oxide; p53; VGX 1027; YY1

Indexed keywords

3 PHENYL 4,5 DIHYDRO 5 ISOXAZOLE ACETIC ACID; 3 PHENYL 4,5 DIHYDRO 5 ISOXAZOLE ACETIC ACID NITRIC OXIDE; GIT 27NO; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN P53; SCAVENGER; TRANSCRIPTION FACTOR YY1; VGX 1027;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CULTURE; CELL DIVISION; CELL PROLIFERATION; CELL VIABILITY; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; INHIBITION KINETICS; INTERNALIZATION; MELANOMA CELL; MITOCHONDRIAL RESPIRATION; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ACETIC ACIDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MELANOMA; NITRIC OXIDE DONORS; OXAZOLES; TUMOR SUPPRESSOR PROTEIN P53; YY1 TRANSCRIPTION FACTOR;

EID: 47149104693     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.niox.2008.04.004     Document Type: Article

References (37)

1. Keeble J.E., and Moore P.K. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Brit. J. Pharmacol. 137 (2002) 295-310
2. Rigas B., and Kashfi K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol. Med. 10 (2004) 324-330
3. Kashfi K., Ryan Y., Qiao L.L., Williams J.L., Chen J., Del Soldado P., Traganos F., and Rigas B. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J. Pharmacol. Exp. Ther. 303 (2002) 1273-1282
4. Ouyang N., Williams J.L., Tsioulias G.J., Gao J., Iatropoulos M.J., Kopelovich L., Kashfi K., and Rigas B. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res. 66 (2006) 4503-4511
5. Nath N., Labaze G., Rigas B., and Kashfi K. NO-donating aspirin inhibits the growth of leukemic Jurkat cells and modulates beta-catenin expression. Biochem. Biophys. Res. Commun. 326 (2005) 93-99
6. Bak A.W., McKnight W., Li P., Del Soldato P., Calignano A., Cirino G., and Wallace J.L. Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci. 62 (1998) 367-373
7. Williams J.L., Kashfi K., Ouyang N., Del-Soldato P., Kopelovich L., and Rigas B. NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. Biochem. Biophys. Res. Commun. 313 (2004) 784-788
8. Yeh R.K., Chen J., Williams J.L., Baluch M., Hundley T.R., Rosenbaum R.E., Kalala S., Traganos F., Benardini F., del Soldato P., Kashfi K., and Rigas B. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property?. Biochem. Pharmacol. 67 (2004) 2197-2205
9. Gao J., Liu X., and Rigas B. Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc. Natl. Acad. Sci. USA 102 (2005) 17207-17212
10. Tarr J.M., Eggleton P., and Winyard P.G. Nitric oxide and the regulation of apoptosis in tumour cells. Curr. Pharm. Des. 12 (2006) 4445-4468
11. Li C.Q., and Wogan G.N. Nitric oxide as a modulator of apoptosis. Cancer Lett. 226 (2005) 1-15
12. Garbán H.J., and Bonavida B. Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J. Immunol. 167 (2001) 75-81
13. Bonavida B., Khineche S., Huerta-Yepez S., and Garban H. Therapeutic potential of nitric oxide in cancer. Drug Resist. Updat. 9 (2002) 157-173
14. Baritaki S., Huerta-Yepez S., Sakai T., Spandidos D.A., and Bonavida B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol. Cancer. Ther. 4 (2007) 1387-1399
15. Gordon S., Akopyan G., Garban H., and Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 25 (2006) 1125-1142
16. Kröncke K.D., and Carlberg C. Inactivation of zinc finger transcription factors provides a mechanism for a gene regulatory role of nitric oxide. FASEB J. 14 (2000) 166-173
17. Shinyashiki M., Chiang K.T., Switzer C.H., Gralla E.B., Valentine J.S., Thiele D.J., and Fukuto J.M. The interaction of nitric oxide (NO) with the yeast transcription factor Ace1: a model system for NO-protein thiol interactions with implications to metal metabolism. Proc. Natl. Acad. Sci. USA 97 (2000) 2491-2496
18. Stojanovic I., Cuzzocrea S., Mangano K., Mazzon E., Miljkovic Dj., Wang M., Donia M., Al-Abed Y., Kim J., Nicoletti F., Stosic-Grujicic S., and Claesson M. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clin. Immunol. 123 (2007) 311-323
19. Stosic-Grujicic S., Cvetkovic I., Mangano K., Fresta M., Maksimovic-Ivanic D., Harhaji Lj., Popadic D., Momcilovic M., Miljkovic Dj., Kim J., Al-Abed Y., and Nicoletti F. A potent immunomodulatory compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice. J. Pharmacol. Exp. Ther. 320 (2007) 1038-1049
20. Kashfi K., and Rigas B. The mechanism of action of nitric oxide-donating aspirin. Biochem. Biophys. Res. Commun. 358 (2007) 1096-1101
21. Maksimovic-Ivanic D., Mijatovic S., Harhaji Lj., Miljkovic Dj., Dabideen D., Fan Cheng K., Mangano K., Malaponte G., Al-Abed Y., Libra M., Garotta G., Nicoletti F., and Stosic-Grujicic S. Anti-cancer properties of the novel nitric oxide- donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide (GIT-27NO) in vitro and in vivo. Mol. Canc. Ther. 7 (2008) 510-520
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
23. Flick D.A., and Gifford G.E. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J. Immunol. Methods 68 (1984) 167-175
24. Decker T., and Lohmann-Matthes M.L. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods 115 (1988) 61-69
25. Kang W., Nielsen O., Fenger C., Leslie G., Holmskov U., and Reid K.B. Induction of DMBT1 expression by reduced ERK activity during a gastric mucosa differentiation-like process and its association with human gastric cancer. Carcinogenesis 26 (2005) 1129-1137
26. Mijatovic S., Maksimovic-Ivanic D., Radovic J., Miljkovic D., Harhaji L., Vuckovic O., Stosic-Grujicic S., Mostarica-Stojkovic M., and Trajkovic V. Anti-glioma action of aloe emodin: the role of ERK inhibition. Cell. Mol. Life Sci. 62 (2005) 589-598
27. Kanzawa T., Germano I.M., Komata T., Ito H., Kondo Y., and Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 11 (2004) 448-457
28. Versteeg H.H., Nijhuis E., van den Brink G.R., Evertzen M., Pynaert G.N., Van Deventer S.J., Coffer P.J., and Peppelenbosch M.P. A new phosphospecific cell-based ELISA for p42/p44 mitogen-activated protein kinase (MAPK), p38 MAPK, protein kinase B and cAMP-response-element-binding protein. Biochem. J. 350 (2000) 717-722
29. Grönroos E., Terentiev A.A., Punga T., and Ericsson J. YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress. Proc. Natl. Acad. Sci. USA 101 (2004) 12165-12170
30. Mijatovic S., Maksimovic-Ivanic D., Radovic J., Popadic D., Momcilovic M., Harhaji L., Miljkovic D., and Trajkovic V. Aloe-emodin prevents cytokine-induced tumor cell death: the inhibition of auto-toxic nitric oxide release as a potential mechanism. Cell. Mol. Life Sci. 61 (2004) 1805-1815
31. Huguenin S., Vacherot F., Fleury-Feith J., Riffaud J.P., Chopin D.K., Bolla M., and Jaurand M.C. Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines. Cancer Lett. 218 (2005) 163-170
32. Blaise G.A., Gauvin D., Gangal M., and Authier S. Nitric oxide, cell signaling and cell death. Toxicology 208 (2005) 177-192
33. Kröncke K.D. Zinc finger proteins as molecular targets for nitric oxide-mediated gene regulation. Antioxid. Redox Signal. 3 (2001) 565-575
34. Kröncke K.D., Fehsel K., Suschek C., and Kolb-Bachofen V. Inducible nitric oxide synthase-derived nitric oxide in gene regulation, cell death and cell survival. Int. Immunopharmacol. 1 (2001) 1407-1420
35. Sui G., Affar e.B., Shi Y., Brignone C., Wall N.R., Yin P., Donohoe M., Luke M.P., Calvo D., Grossman S.R., and Shi Y. Yin Yang 1 is a negative regulator of p53. Cell 117 (2004) 859-872
36. Yao Y.L., Dupont B.R., Ghosh S., Fang Y., Leach R.J., and Seto E. Cloning, chromosomal localization and promoter analysis of the human transcription factor YY1. Nucleic Acids Res. 26 (1998) 3776-3783
37. Joshi B., Rastogi S., Morris M., Carastro L.M., DeCook C., Seto E., and Chellappan S.P. Differential regulation of human YY1 and caspase 7 promoters by prohibitin through E2F1 and p53 binding sites. Biochem. J. 401 (2007) 155-166